Weekly Digest - September 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - September 2024
18 Sep 2024: Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
- Zymeworks will present preclinical data for their antibody-drug conjugate (ADC) candidates ZW220 and ZW251 at the EORTC-NCI-AACR Conference in Barcelona from October 23-25, 2024
- ZW220 targets NaPi2b and has shown promising activity in non-small cell lung, ovarian, and uterine cancer models, while ZW251 targets glypican-3 and has shown compelling results in hepatocellular carcinoma models
- Both ADC candidates utilize Zymeworks’ proprietary payload, ZD06519, contributing to their therapeutic potential
- The company is on track for Investigational New Drug (IND) filings for ZW220 and ZW251 in 2025, building on the advancement of other candidates, ZW171 and ZW191, which are currently in Phase 1 studies
